GLP-1 Before Surgery: Anesthesia and Preparation

Tell your anesthesia and procedure teams that you take a GLP-1 medicine, and get one agreed medication and fasting plan before the appointment. There is no stopping interval that this article can safely assign to everyone taking semaglutide or tirzepatide. Do not choose between conflicting instructions on your own.

This includes procedures with deep sedation, such as some endoscopies, as well as surgery under general anesthesia. Sources checked October 11, 2026.

Why the team needs to know#

These medicines can delay stomach emptying. Food remaining in the stomach can enter the airway during anesthesia or deep sedation, causing aspiration. Following an ordinary fasting schedule does not automatically answer whether a particular patient's stomach is empty. The American Society of Anesthesiologists (ASA) asks patients to disclose these medicines and discuss risk reduction with their care team. ASA patient information

Give the team the exact product, whether it is a tablet or injection, dose, usual schedule, last dose and recent dose changes. Include nonprescription or research-labelled products: a different label does not make medication disclosure unnecessary.

Why one page says “continue” and another says “hold”#

The 2024 U.S. multisociety guidance permits continuation in patients without elevated risk, while weighing a possible hold against metabolic risks such as high blood glucose. It considers dose escalation, higher doses, gastrointestinal symptoms and other conditions that delay stomach emptying. If a hold is chosen, it acknowledges that the effective duration is unknown; its suggested daily/weekly intervals are a clinical planning reference, not proof of an empty stomach. Original multisociety guidance

ASA's patient guidance describes possible clinician-directed measures: a modified diet, stomach ultrasound, a changed anesthesia plan or postponement. The choice depends on the patient and procedure. Stopping the medicine and changing the diet answer different parts of that assessment. ASA patient information

Country and service policies also matter. ANZCA's current Australian and New Zealand recommendations advise against routine elective cessation and recommend a 24-hour clear-fluid diet with subsequent local fasting instructions. Its web guidance includes an April 2026 clarification about those fasting instructions. Do not combine an interval from one country's guidance with a fasting rule from another. ANZCA recommendations and patient documents

What the 2026 endoscopy trial adds#

The OCULUS randomized trial analyzed 60 adults taking stable doses who underwent upper endoscopy with sedation. Clinically significant retained gastric volume occurred in 25.0% of those continuing medication and 3.1% of those holding a dose. The trial stopped early. All such events prevented adequate examination; none were aspiration events. Planned general anesthesia and documented gastroparesis were among the exclusions.

No primary events occurred in the 25-person subgroup also having colonoscopy and its clear-liquid preparation. That subgroup was not a randomized test of the diet itself and cannot establish that a liquid diet eliminates risk. Neither can this small trial establish a safe stopping interval for every operation or measure rare aspiration risk reliably. It does show why procedure context and a specific preparation plan matter. OCULUS methods, results and limitations

Resolve conflicting instructions before the procedure#

Ask the procedure service to reconcile its instructions with the prescriber and anesthesia team. A useful message is:

“I take [product and dose], usually on [schedule]. My last dose was [date], and my most recent dose change was [date]. I received different instructions about stopping and fasting. Please confirm one plan for my procedure, including what to do if I have already taken a dose.”

Get answers to these separate questions:

• Medication: Continue or hold, on which dates, and who manages glucose if treatment changes?
• Preparation: Which foods and liquids are allowed, and when does each stop?
• Symptoms: Whom should you contact about nausea, vomiting, abdominal pain or constipation?
• Changes: What happens if the procedure date changes or preparation was not followed?
• Afterwards: Who confirms when and how treatment resumes?

If you already took a dose or missed preparation, tell the team promptly rather than conceal it or assume cancellation. For urgent care, disclose the medicine and last dose immediately; do not delay emergency assessment to complete a self-selected washout.

For a separate symptom question, see our GLP-1 hair-shedding guide. Its treatment timeline does not determine anesthesia preparation. For your appointment, use the linked anesthesia resources and your own procedure team's written plan.